Dyne doses first patient in DYNE-251 DMD trial, initiates DYNE-101 DM1 trial, defers FSHD IND

Dyne Therapeutics, Inc.

First patient dosed in Phase 1/2 DELIVER trial of DYNE-251 for DMD exon 51 skipping; registrational trial targeting ~46 patients.
Initiated Phase 1/2 ACHIEVE trial for DYNE-101 in DM1; first patient expected in September 2022; target ~64 adult patients.
Deferring IND submission for DYNE-301 (FSHD) originally planned for H2 2022; update expected in 2023.
Cash runway extended through 2024 due to FSHD program deferral, based on existing cash and equivalents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.